---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-066856"
form_type: "8-K"
ticker: "SABS"
cik: "0001833214"
company_name: "SAB Biotherapeutics, Inc."
filed_at: "2024-05-31T23:59:59+00:00"
generated_at: "2026-06-01T07:14:04.770822+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# SAB Biotherapeutics CFO Michael King resigns effective June 4; Mark Conley appointed Interim CFO

## Summary
- CFO Michael King resigns effective June 4, 2024 to become CEO at private oncology company; will remain advisor through year-end.
- Mark Conley, current VP Finance, appointed Interim CFO; board launches formal search for permanent replacement.
- Conley's compensation unchanged under existing agreement: $303K base salary, bonus eligibility, and 250,000 stock options.
- Company confirms FY2024 outlook and upcoming Phase 1 topline data readout for lead candidate SAB-142.

## SEC filing metadata
- accession: 0000950170-24-066856
- form_type: 8-K
- ticker: SABS
- cik: 0001833214
- company_name: SAB Biotherapeutics, Inc.
- filed_at: 2024-05-31T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1833214/000095017024066856/0000950170-24-066856-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1833214/000095017024066856/sabs-20240526.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-066856
- JSON: https://secwatch.observer/filing/0000950170-24-066856.json
- Plain text: https://secwatch.observer/filing/0000950170-24-066856.txt

## Key facts
- Executive change
  Mark Conley was appointed as Interim Chief Financial Officer at SAB Biotherapeutics, Inc..
  - Action: appointed
  - Role: Interim Chief Financial Officer
  source text: On May 30, 2024, Mark Conley, 62, was appointed Interim Chief Financial Officer of SAB Biotherapeutics, Inc., a Delaware corporation (the “Company”), effective June 4, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1833214/000095017024066856/0000950170-24-066856-index.htm
- Executive change
  Michael King, Jr. resigned as Chief Financial Officer at SAB Biotherapeutics, Inc..
  - Action: resigned
  - Role: Chief Financial Officer
  source text: On May 26, 2024, Michael King, Jr., Chief Financial Officer of the Company, informed the Company that he will resign from his position with the Company, effective June 4, 2024, to pursue another opportunity.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1833214/000095017024066856/0000950170-24-066856-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.